AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1). Building a credible third-tier biopharma franchise behind Lilly and Novo.
AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1). Building a credible third-tier biopharma franchise behind Lilly and Novo.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling: